Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides †
Abstract
:Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szafrański, K.; Sławiński, J.; Kawiak, A. Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides. Med. Sci. Forum 2022, 14, 51. https://doi.org/10.3390/ECMC2022-13280
Szafrański K, Sławiński J, Kawiak A. Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides. Medical Sciences Forum. 2022; 14(1):51. https://doi.org/10.3390/ECMC2022-13280
Chicago/Turabian StyleSzafrański, Krzysztof, Jarosław Sławiński, and Anna Kawiak. 2022. "Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides" Medical Sciences Forum 14, no. 1: 51. https://doi.org/10.3390/ECMC2022-13280
APA StyleSzafrański, K., Sławiński, J., & Kawiak, A. (2022). Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides. Medical Sciences Forum, 14(1), 51. https://doi.org/10.3390/ECMC2022-13280